Biliary atresia: feasibility of mangafodipir trisodium-enhanced MR cholangiography for evaluation.
The study was approved by the institutional review board, and informed consent was obtained from the patients' parents. Twenty-three consecutive infants suspected of having biliary atresia (BA) were prospectively examined by using mangafodipir trisodium (Mn-DPDP)-enhanced magnetic resonance (MR) cholangiography. Sequential T1-weighted spoiled gradient-echo MR cholangiograms were obtained 1, 2, and 3 hours after intravenous administration of Mn-DPDP. The possibility of BA was excluded if bowel excretion of contrast material was noted at contrast material-enhanced MR cholangiography. The diagnostic specificity and accuracy of contrast-enhanced MR cholangiography were compared with those of conventional MR cholangiography, technetium 99m Tc ((99m)Tc)-disofenin (DISIDA) scintigraphy, and the triangular cord sign at ultrasonography (US). MR cholangiography was used to accurately distinguish four cases of BA from 19 cases of other cholestatic liver diseases, without false-positive results. Conventional MR cholangiography, (99m)Tc-DISIDA scintigraphy, and the triangular cord sign at US respectively yielded false-positive results of 42% (eight of 19 infants), 35% (six of 17 infants), and 11% (two of 19 infants) in patients without BA. Mn-DPDP-enhanced MR cholangiography appears to be a promising modality for early diagnosis of BA as the cause of neonatal cholestasis.
Ryeom
Hun Kyu
HK
Department of Radiology, Kyungpook National University School of Medicine, Samduk 2Ga, Jung-Gu, Daegu 700-721, Republic of Korea.
Choe
Byung Ho
BH
Kim
Jong Yeol
JY
Kwon
Soonhak
S
Ko
Cheol Woo
CW
Kim
Heng Mi
HM
Lee
Sang Bum
SB
Kang
Duk Sik
DS
D001656:Biliary Atresia / Q000175:diagnosis*; D002758:Cholangiography / Q000379:methods*; D003287:Contrast Media; D004492:Edetic Acid / Q000031:analogs & derivatives*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008279:Magnetic Resonance Imaging; D008297:Male; D011446:Prospective Studies; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives*; D012680:Sensitivity and Specificity
D003287:Contrast Media; D011732:Pyridoxal Phosphate; D004492:Edetic Acid; C060076:N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid